PRKAA2 and acute myeloid leukemia: In contrast to other tissues in which both AMPK α1 and α2 isoforms are expressed, hematopoietic cells lack AMPKα2 expression, even after AMPKα1 invalidation, allowing a complete inhibition of AMPK activity in AML cells with a single CRISPR/Cas9 sgRNA targeting PRKAA1 [19].